Plasma amyloid-β oligomers level is a biomarker for Alzheimer's disease diagnosis

Biochemical and Biophysical Research Communications

Volumn 423, Issue 4, 2012, Pages 697-702

  Zhou, L ^a   Chan, K H ^a   Chu, L W ^a   Kwan, J S C ^a   Song, Y Q ^a,b   Chen, L H ^b   Ho, P W L ^a   Cheng, O Y ^a   Ho, J W M ^a   Lam, K S L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Alzheimer's disease; Amyloid beta oligomers; Biomarker; Cognitive functions; ELISA; Plasma amyloid beta oligomers level

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; OLIGOMER;

ABBREVIATED METAL TEST; ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMERS DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SCORING SYSTEM; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CHINA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS;

EID: 84863812366     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.06.017     Document Type: Article

References (45)

1. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007, 3:186-191.
2. Querfurth H.W., LaFerla F.M. Mechanism of disease: Alzheimer's Disease. N. Engl. J. Med. 2010, 362:329-344.
3. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
4. Gravina S.A., Ho L., Eckman C.B., Long K.E., Otvos L., Younkin L.H., Suzuki N., Younkin S.G. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J. Biol. Chem. 1995, 270:7013-7016.
5. Schupf N., Patel B., Silverman W., Zigman W.B., Zhong N., Tycko B., Mehta P.D., Mayeux R. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci. Lett. 2001, 301:199-203.
6. Zlokovic B.V. Clearing amyloid through the blood-brain barrier. J. Neurochem. 2004, 89:807-811.
7. Tanzi R.E., Moir R.D., Wagner S.L. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 2004, 43:605-608.
8. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 2008, 192:106-113.
9. Glabe C.G. Structural classification of toxic amyloid oligomers. J. Biol. Chem. 2008, 283:29639-29643.
10. Walsh D.M., Selkoe D.J. Aβ oligomers: a decade of discovery. J. Neurochem. 2007, 101:1172-1184.
11. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
12. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E. St George-Hyslop, P., and Westaway, D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
13. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
14. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916-919.
15. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A.L., Manea M., French J.E., Lambermon M.H., Darabie A.A., Brown M.E., Janus C., Chishti M.A., Horne P., Westaway D., Fraser P.E., Mount H.T., Przybylski M. And St George-Hyslop, P, Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 2002, 8:1263-1269.
16. Dodel R.C., Du Y., Depboylu C., Hampel H., Frolich L., Haag A., Hemmeter U., Paulsen S., Teipel S.J., Brettschneider S., Spottke A., Nolker C., Moller H.J., Wei X., Farlow M., Sommer N., Oertel W.H. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2004, 75:1472-1474.
17. Relkin N.R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R.W., Younkin S., Younkin L., Schiff R., Weksler M.E. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 2009, 30:1728-1736.
18. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's Disease. Neurology 1984, 34:939-944.
19. Klein W.L. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 2002, 41:345-352.
20. Tamaoka A., Fukushima T., Sawamura N., Ishikawa K., Oguni E., Komatsuzaki Y., Shoji S. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J. Neurol. Sci. 1996, 141:65-68.
21. Fukumoto H., Tennis M., Locascio J.J., Hyman B.T., Growdon J.H., Irizarry M.C. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch. Neurol. 2003, 60:958-964.
22. Mayeux R., Tang M.X., Jacobs D.M., Manly J., Bell K., Merchant C., Small S.A., Stern Y., Wisniewski H.M., Mehta P.D. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann. Neurol. 1999, 46:412-416.
23. Mayeux R., Honig L.S., Tang M.X., Manly J., Stern Y., Schupf N., Mehta P.D. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003, 61:1185-1190.
24. Mehta P.D., Pirttila T., Mehta S.P., Sersen E.A., Aisen P.S., Wisniewski H.M. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 2000, 57:100-105.
25. Graff-Radford N. Analysis of plasma Aβ42 as a premorbid marker for late onset Alzheimer's disease. Neurobiol. Aging 2004, 25:354.
26. Baranowska-Bik A., Bik W., Wolinska-Witort E., Martynska L., Chmielowska M., Barcikowska M., Baranowska B. Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. Neuro. Endocrinol. Lett. 2008, 29:75-79.
27. Pitschke M., Prior R., Haupt M., Riesner D. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat. Med. 1998, 4:832-834.
28. Santos A.N., Simm A., Holthoff V., Boehm G. A method for the detection of amyloid-beta1-40, amyloid-beta1-42 and amyloid-beta oligomers in blood using magnetic beads in combination with flow cytometry and its application in the diagnostics of Alzheimer's disease. J. Alzheimers Dis. 2008, 14:127-131.
29. Xia W., Yang T., Shankar G., Smith I.M., Shen Y., Walsh D.M., Selkoe D.J. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch. Neurol. 2009, 66:190-199.
30. Tomic J.L., Pensalfini A., Head E., Glabe C.G. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol. Disease 2009, 35:352-358.
31. Chen L.H., Kao P.Y., Fan Y.H., Ho D.T., Chan C.S., Yik P.Y., Ha J.C., Chu L.W., Song Y.Q. Polymorphisms of CR1, CLU and PICALM confer susceptibility of Alzheimer's disease in a southern Chinese population. Neurobiology of Aging 2012, 33:210e1-210e7.
32. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 1998, 95:6448-6453.
33. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E. Rogers J Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer disease. Am. J. Pathol. 1999, 155:853-862.
34. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Masters C.L. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer disease. Ann. Neurol. 1999, 46:860-866.
35. Katzman R., Terry R., DeTeresa R., Brown T., Davies P., Fuld P., Renbing X., Peck A. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 1988, 23:138-144.
36. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
37. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., Viola K.L., Lambert M.P., Velasco P.T., Bigio E.H., Finch C.E., Krafft G.A., Klein W.L. Synaptic targeting by Alzheimer's-related amyloid β oligomers. J. Neurosci. 2004, 24:10191-10200.
38. Lesné S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
39. Lacor P.N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., Viola K.L., Klein W.L. Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 2007, 27:796-807.
40. Shankar G.M., Blood good B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor dependent signaling pathway. J. Neurosci. 2007, 27:2866-2875.
41. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-β protein dimers isolated directly from Alzheimer's brain impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
42. Hillen H., Barghorn S., Striebinger A., Labkovsky B., Müller R., Nimmrich V., Nolte M.W., Perez-Cruz C., van der Auwera I., van Leuven F., van Gaalen M., Bespalov A.Y., Schoemaker H., Sullivan J.P., Ebert U. Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J. Neurosci. 2010, 30:10369-10379.
43. van Helmond Z., Heesom K., Love S. Characterisation of two antibodies to oligomeric A beta and their use in ELISAs on human brain tissue homogenates. J. Neurosci. Meth. 2009, 176:206-212.
44. Townsend M., Shankar G.M., Mehta T., Walsh D.M., Selkoe D.J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 2006, 572:477-492.
45. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 2003, 100:10417-10422.